Number Т. 10, № 3-4 (39-40)

The role of immunotherapy in the complex treatment of patients with oral cancer: a view of a clinical oncologist

Korobko Y.

Summary. The development of immunotherapy has become possible on the basis of studying the tumor escape mechanisms from the immune response by binding the PD-1 protein with the corresponding PD-L1 ligand, which is expressed on the surface of the tumor cell. Improving the results of treatment when prescribing anti-PD-1 antibody pembrolizumab occurs due to blocking the interaction between PD-1 and PD-L1, which prevents the tumor cell from interaction with activated T-lymphocyte, triggering natural mechanisms of antitumor cellular immunity.Key words: head and neck cancer; oral cancer; immunotherapy; PD-1; PD-L1.
No Comments » Add your
Leave a comment